Characteristics of the specific humoral response in patients with advanced solid tumors after active immunotherapy with a VEGF vaccine, at different antigen doses and using two distinct adjuvants

BACKGROUND: CIGB-247, a VSSP-adjuvanted VEGF-based vaccine, was evaluated in a phase I clinical trial in patients with advanced solid tumors (CENTAURO). Vaccination with the maximum dose of antigen showed an excellent safety profile, exhibited the highest immunogenicity and was the only one showing...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez Ramírez, Javier, Morera Díaz, Yanelys, Bequet-Romero, Mónica, Hernández-Bernal, Francisco, Selman-Housein Bernal, Katty-Hind, de la Torre Santos, Ana, Santiesteban Álvarez, Eduardo Rafael, Martín Bauta, Yenima, Bermúdez Badell, Cimara H., de la Torre Pupo, Josué, Gavilondo, Jorge V., Ayala Avila, Marta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530503/
https://www.ncbi.nlm.nih.gov/pubmed/28747172
http://dx.doi.org/10.1186/s12865-017-0222-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5530503/
https://www.ncbi.nlm.nih.gov/pubmed/28747172
http://dx.doi.org/10.1186/s12865-017-0222-z

Ejemplares similares